Allarity expands Phase 2 trial of stenoparib in advanced ovarian cancer; enrollment targets H1 2025

Allarity Therapeutics, Inc.

New Phase 2 protocol focuses on advanced, recurrent, platinum-resistant ovarian cancer patients.
Trial aims to optimize stenoparib dose and refine DRP patient selection criteria for companion diagnostic.
Some patients on stenoparib for over 14 months demonstrate durable clinical benefit.
Enrollment expected to begin first half of 2025, subject to regulatory approval including FDA review.
Stenoparib is a dual PARP/Wnt inhibitor; trial will investigate Wnt pathway impact to differentiate treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.